Literature DB >> 27234603

Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer.

Masaya Yotsukura1, Takashi Ohtsuka1, Kaoru Kaseda1, Ikuo Kamiyama1, Yuichiro Hayashi2, Hisao Asamura3.   

Abstract

BACKGROUND: Over the past decade, the Glasgow prognostic score (GPS), which is based on serum C-reactive protein and albumin levels, has been reported to be associated with the prognosis of patients with several types of inoperable and operable cancers. However, its applicability to operable non-small cell lung cancer (NSCLC) has not yet been established.
METHODS: We retrospectively collected data from patients with pathological stage I or II NSCLC who underwent complete resection. A total of 1048 patients were categorized as either GPS-0 (n = 817 [78.0%]), GPS-1 (184 [17.6%]), or GPS-2 (47 [4.5%]). Survival curves were estimated using the Kaplan-Meier method, and the Cox proportional hazard model was used to analyze the relationship between prognosis and GPS status.
RESULTS: The 5-year overall survival (OS) rates were 91.2%, 78.3%, and 75.8% for GPS-0, GPS-1, and GPS-2, respectively. There were significant differences in OS between GPS-0 and GPS-1 (p < 0.001) and between GPS-0 and GPS-2 (p < 0.001). Ten variables demonstrated to be associated with OS in a univariate analysis were subjected to a multivariate analysis. The results showed that male sex (p = 0.031), vascular invasion (p < 0.001), lymph node metastasis (p < 0.001), and GPS (p = 0.025) were significantly associated with OS.
CONCLUSIONS: A high GPS is significantly associated with poor OS. Although the biological mechanism that underlies this association is not clear, this inflammation-based score may be a useful indicator of the prognosis in patients with resectable NSCLC.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Lung cancer; Prognostic factor; Surgery

Mesh:

Substances:

Year:  2016        PMID: 27234603     DOI: 10.1016/j.jtho.2016.04.029

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  18 in total

1.  Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer.

Authors:  Murat Yigit; Serkan Değirmencioğlu; Erhan Ugurlu; Arzu Yaren
Journal:  Mol Clin Oncol       Date:  2017-03-15

2.  Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Authors:  Marianna Grinberg; Dijana Djureinovic; Hans Rr Brunnström; Johanna Sm Mattsson; Karolina Edlund; Jan G Hengstler; Linnea La Fleur; Simon Ekman; Hirsh Koyi; Eva Branden; Elisabeth Ståhle; Karin Jirström; Derek K Tracy; Fredrik Pontén; Johan Botling; Jörg Rahnenführer; Patrick Micke
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

3.  Inflammation-Based Prognostic Score Predicts Postoperative Survival of Patients with Interstitial Pneumonia After Undergoing Lung Cancer Resection.

Authors:  Satoru Kobayashi; Yuji Matsumura; Yoko Karube; Morimichi Nishihira; Takashi Inoue; Osamu Araki; Sumiko Maeda; Masayuki Chida
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

4.  Advanced Lung Cancer Inflammation Index is a Prognostic Factor of Patients with Small-Cell Lung Cancer Following Surgical Resection.

Authors:  Zhonghui Hu; Wenbo Wu; Ping Li; Xiaopeng Zhang; Hua Zhang; Huien Wang; Wenfei Xue; Zhiguo Chen; Qingtao Zhao; Guochen Duan
Journal:  Cancer Manag Res       Date:  2021-02-26       Impact factor: 3.989

5.  Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer.

Authors:  G Jomrich; M Paireder; A Gleiss; I Kristo; L Harpain; S F Schoppmann
Journal:  Gastroenterol Res Pract       Date:  2017-06-27       Impact factor: 2.260

6.  Prognostic role of Glasgow prognostic score in patients with colorectal cancer: evidence from population studies.

Authors:  Yangyang Liu; Xingkang He; Jie Pan; Shujie Chen; Liangjing Wang
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

7.  Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study.

Authors:  Jin-Rong Yang; Jia-Ying Xu; Guo-Chong Chen; Na Yu; Jing Yang; Da-Xiong Zeng; Min-Jing Gu; Da-Peng Li; Yu-Song Zhang; Li-Qiang Qin
Journal:  Sci Rep       Date:  2019-05-31       Impact factor: 4.379

8.  Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma.

Authors:  Xiaoxiao Hao; Yongqiang Wei; Xiaolei Wei; Lizhi Zhou; Qi Wei; Yuankun Zhang; Weimin Huang; Ru Feng
Journal:  Oncotarget       Date:  2017-09-11

9.  The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation.

Authors:  Hanno M Witte; Bastian Bonorden; Armin Riecke; Harald Biersack; Konrad Steinestel; Hartmut Merz; Alfred C Feller; Veronica Bernard; Sebastian Fetscher; Nikolas von Bubnoff; Niklas Gebauer
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

10.  Advanced Lung Cancer Inflammation Index Predicts Outcomes of Patients with Pathological Stage IA Lung Adenocarcinoma Following Surgical Resection.

Authors:  Satoru Kobayashi; Yoko Karube; Takashi Inoue; Osamu Araki; Sumiko Maeda; Yuji Matsumura; Masayuki Chida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-10-17       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.